Merck’s Capvaxive becomes first PCV approved specifically for high-risk children aged 2-17

Edited by Robert McTiernan··2 min read

Merck (NYSE: MRK) has received US FDA approval for an expanded indication related toCapvaxive (pneumococcal 21-valent conjugate vaccine), extending its use to children and adolescents aged 2 through 17 years at increased risk for pneumococcal disease — making it the only pneumococcal conjugate vaccine (PCV) specifically indicated and studied in the US for this high-risk pediatric population.

The expanded indication covers individuals who have completed a primary pediatric pneumococcal vaccination series and have one or more chronic medical conditions — including diabetes, chronic heart disease, chronic kidney disease, chronic liver disease, or chronic lung disease — that elevate their risk for invasive pneumococcal disease (IPD). Capvaxive is administered as a single dose and is intended to complement, rather than replace, existing primary pediatric vaccination schedules.

The vaccine targets 21 Streptococcus pneumoniae serotypes, including 8 not covered by other approved pneumococcal vaccines. The approval was supported by STRIDE-13 (NCT06177912), a Phase III randomized trial in 874 high-risk pediatric participants who had completed a primary pneumococcal vaccination series. Capvaxive demonstrated noninferiority to PPSV23, with a broadly comparable safety profile.

The AllSci BriefSystematic R&D and deal news. Daily.

The pediatric competitive landscape is occupied primarily by Pfizer’s Prevnar 20 (PCV20), approved for children aged 6 weeks through 17 years in April 2023, and Merck’s own Vaxneuvance (PCV15), approved in the same age range in April 2022. Capvaxive’s 22-serotype panel offers broader coverage than either, though the clinical significance of that expanded serotype breadth in terms of disease prevention outcomes remains to be established in efficacy trials. Pfizer is also advancing a 25-valent pneumococcal conjugate vaccine into Phase III, with a pediatric program underway, and has disclosed a 35-valent fifth-generation candidate entering early clinical development — signaling continued serotype escalation across the field.

Capvaxive’s broader serotype coverage could provide an advantage in high-risk pediatric populations, although the clinical impact of that expanded coverage on disease prevention outcomes remains to be established.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/